Literature DB >> 2466481

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.

D M Lowe1, A Aitken, C Bradley, G K Darby, B A Larder, K L Powell, D J Purifoy, M Tisdale, D K Stammers.   

Abstract

Bacterially expressed recombinant HIV-1 reverse transcriptase is active as both a homodimer of Mr 66,000 subunits and a heterodimer of Mr 66,000 and 51,000 subunits. The heterodimer is formed by cleavage of a C-terminal fragment from one Mr 66,000 polypeptide, which occurs during purification and crystallization of reverse transcriptase. Thus, crystals obtained from purified Mr 66,000 polypeptide preparations consisted of an apparently equimolar mixture of Mr 66,000 and 51,000 polypeptides, which were apparently analogous to the Mr 66,000 and 51,000 polypeptides detected in HIV-infected cells and in virions. Limited proteolysis of the homodimer with alpha-chymotrypsin also resulted in cleavage to a stable Mr 66,000/51,000 mixture, and proteolysis with trypsin resulted in the transient formation of some Mr 51,000 polypeptide. These results are consistent with the reverse transcriptase molecule having a protease-sensitive linker region following a structured domain of Mr 51,000. Further digestion with trypsin resulted in cleavage of the Mr 51,000 polypeptide after residue 223, yielding peptides of apparent Mr 29,000 and 30,000. A minor peptide of Mr 40,000 was also produced by cleavage of the Mr 66,000 polypeptide after residue 223. About half the original Mr 66,000 polypeptides remained resistant to proteolysis and existed in complex with the above peptides in solution. During both chymotrypsin and trypsin digestion there was an increase in the reverse transcriptase activity caused by a doubling of Vmax with little change in Km for dTTP.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2466481     DOI: 10.1021/bi00425a002

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  29 in total

1.  Ty3 integrase is required for initiation of reverse transcription.

Authors:  M Henrietta Nymark-McMahon; Nadejda S Beliakova-Bethell; Jean-Luc Darlix; Stuart F J Le Grice; Suzanne B Sandmeyer
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

2.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

3.  New surface contacts formed upon reductive lysine methylation: improving the probability of protein crystallization.

Authors:  Pawel Sledz; Heping Zheng; Krzysztof Murzyn; Maksymilian Chruszcz; Matthew D Zimmerman; Mahendra D Chordia; Andrzej Joachimiak; Wladek Minor
Journal:  Protein Sci       Date:  2010-07       Impact factor: 6.725

4.  Domain structure and three-dimensional model of a group II intron-encoded reverse transcriptase.

Authors:  Forrest J H Blocker; Georg Mohr; Lori H Conlan; Li Qi; Marlene Belfort; Alan M Lambowitz
Journal:  RNA       Date:  2004-12-01       Impact factor: 4.942

5.  Crystals of a ternary complex of human immunodeficiency virus type 1 reverse transcriptase with a monoclonal antibody Fab fragment and double-stranded DNA diffract x-rays to 3.5-A resolution.

Authors:  A Jacobo-Molina; A D Clark; R L Williams; R G Nanni; P Clark; A L Ferris; S H Hughes; E Arnold
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

6.  Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase.

Authors:  S F Le Grice; M Panin; R C Kalayjian; N J Richter; G Keith; J L Darlix; S L Payne
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

7.  Enzyme activities in four different forms of human immunodeficiency virus 1 pol gene products.

Authors:  Y W Hu; C Y Kang
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 8.  Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise.

Authors:  Stuart F J Le Grice
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

9.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616

10.  The "Connection" Between HIV Drug Resistance and RNase H.

Authors:  Krista A Delviks-Frankenberry; Galina N Nikolenko; Vinay K Pathak
Journal:  Viruses       Date:  2010-07-01       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.